Ugur Sahin

Global corporate and market sector trends

2 clusters · 13 sources · last updated 14 days ago

Latest: Global markets face regulatory fees for UBS and shifting analyst targets

Global financial markets continue to show varied activity across the energy, technology, defense, and consumer sectors. In the energy sector, TotalEnergies expanded its renewable footprint through a $1.2 billion joint v

BioNTech strategic transition to oncology focus

2 clusters · 55 sources · last updated 19 days ago

Latest: BioNTech focuses on oncology pipeline amid strategic transition

BioNTech is undergoing a strategic transition from a pandemic-era vaccine manufacturer to a specialized oncology company. Following a decline in global demand for COVID-19 vaccines, the company announced the phased closu

BioNTech corporate developments and oncology expansion

2 clusters · 3 sources · last updated 20 days ago

Latest: BioNTech expands oncology pipeline amid various corporate insider stock sales

BioNTech CEO Ugur Sahin executed multiple stock sales in early September, selling 149,500 shares at prices between approximately $96.31 and $103.52 per share. These transactions were conducted under a pre-arranged Rule 1

BioNTech leadership transition and new company formation

2 clusters · 8 sources · last updated 29 days ago

Latest: BioNTech faces internal disputes amid German political debates

BioNTech founders Uğur Şahin and Özlem Türeci announced the creation of a new Mainz-based pharmaceutical company named Arife. This new entity will focus on the research, development, manufacturing, and marketing of next-